Korean National Health Insurance Covers Novartis Galvus In Second-Line Type 2 Diabetes
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Novartis Korea's DPP-4 inhibitor type 2 diabetes treatment Galvus (vildagliptin) will be covered by South Korea's National Health Insurance Policy beginning Feb. 1 for second-line treatment